Matrixyl vs Liraglutide
Side-by-side comparison of key properties, dosing, and research.
Skin & Cosmetic
MatrixylGLP-1 / Weight Loss AgonistsFat Loss & Metabolic
Liraglutide- Summary
- Matrixyl is the most widely used collagen-stimulating cosmetic peptide. As a matrikine — a fragment of type I procollagen — it signals skin cells to synthesize new collagen, elastin, and fibronectin, reducing wrinkle depth and improving skin firmness and elasticity.
- Liraglutide is a long-acting GLP-1 receptor agonist approved for type 2 diabetes (Victoza) and chronic weight management (Saxenda). It reduces appetite, slows gastric emptying, improves insulin secretion, and promotes weight loss of 5–10% in clinical trials.
- Half-Life
- N/A — topical; sustained signaling effects on fibroblasts persist beyond single application
- ~13 hours (once-daily dosing)
- Admin Route
- Topical
- SubQ
- Research
- —
- —
- Typical Dose
- 3–8% concentration
- Start 0.6 mg, titrate to 3 mg
- Frequency
- Once or twice daily
- Once daily
- Key Benefits
- Stimulates collagen I, III, and IV synthesis
- Increases fibronectin and glycosaminoglycan production
- Reduces wrinkle depth and length by 27–68% (studies)
- Improves skin firmness and elasticity
- Reduces dark circles and undereye bags
- Synergistic with retinol, vitamin C, and growth factors
- Suitable for all skin types including sensitive
- Well-studied with published clinical data
- Promotes weight loss (5–10% average)
- Reduces appetite and caloric intake
- Improves blood glucose control (HbA1c reduction)
- Reduces cardiovascular events in T2DM (LEADER trial)
- Slows gastric emptying
- FDA-approved for T2DM and chronic weight management
- Cardioprotective effects shown in clinical trials
- May improve fatty liver (NAFLD/NASH)
- Side Effects
- Exceptional safety profile
- Non-irritating, suitable for sensitive skin
- No known adverse effects at cosmetic concentrations
- Nausea (very common, especially initially)
- Vomiting
- Diarrhea or constipation
- Decreased appetite
- +5 more
- Stacks With
- —
- —